Health

The economic and social costs of the global lockdown have been astronomical but as governments look to begin the process of reopening economies it will be critical to develop strategies that balance both the health and economic risks of the pandemic.

John Ruskin helps shed light on what it means to have an economy that demands we die for it

The COVID-19 pandemic has thrust us into a new reality, and any course we set now will have huge and lasting repercussions on public health and the economy.

Developing countries, many of which appear not to have felt the health effects of COVID to the same extent as Europe and the US, are nonetheless facing severe economic effects as the pandemic pushes the global economy into a recession.

Evidence shows pharmaceutical companies won’t stop price-gouging and risking American lives for financial gain in this time of crises – unless we force them.

With the COVID-19 death toll rising, we should question the wisdom and morality of an IP system that silently condemns millions of human beings to suffering and death every year.

Researchers have shown that the financial and economic impacts of denying women abortion care can last years

Contrary to pharmaceutical company claims, revenue from high insulin prices are going to shareholders, not R&D

This paper considers the relationship between profits realized from higher insulin list prices, pharmaceutical innovation, and the financial structures of the three dominant insulin manufacturing companies, which set list prices.

A call to action for a world economy in crisis

IMPORTANT: Due to growing concerns around the coronavirus, the INET Conference, as well as these workshops will be postponed. Applicants will soon be provided further information.

The scale of firm exposure to the coronavirus is unprecedented by earlier outbreaks, spans all major economies and is pervasive across all industries

As Covid-19 spreads globally in the first quarter of 2020, this paper finds that firms’ primary concerns relate to the collapse of demand, increased uncertainty, and disruption in supply chains

As we face a coronavirus-induced health and economic crisis of uncertain duration, policy makers should be particularly concerned about private equity’s heightened use of debt to buy out healthcare providers and take them private, with no regulatory oversight.

Private equity firms have become major players in the healthcare industry. How has this happened and what are the results?